University of Washington

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Washington sits in the top decile of US sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count).

1,048 total trials 156 currently recruiting 720 completed early-phase tilt top decile by trial count

University of Washington: 1,048 sponsored US clinical trials, 156 recruiting.

University of Washington sponsors 1,048 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 720 completed. 104 of these trials are in Phase 3-4 (later-stage) and 320 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 13 trials.

Top-decile sponsor footprint

University of Washington ranks in the top decile of sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

720 of 816 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,048 total, page 18 of 21

COMPLETED

HPV Infections in Older Women

NCT00743392
COMPLETED

Immune-cell Membrane Trafficking

NCT00638521
COMPLETED

Cognitive Testing for the Pain Quality Assessment Scale (PQAS)

NCT00715598
COMPLETED Phase 3

ICU Family Communication Study

NCT00720200
COMPLETED Phase 2

Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury

NCT00692575
COMPLETED

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

NCT00880178
COMPLETED Phase 2

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

NCT00733408
COMPLETED Phase 1

VAS-2 Vasectomy With the Vax-X

NCT00663533
COMPLETED NA

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

NCT00809770
COMPLETED Phase 1

Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream

NCT00690625
COMPLETED NA

Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial

NCT00619255
COMPLETED Phase 1

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

NCT00621309
COMPLETED

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

NCT01178320
TERMINATED Phase 1

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

NCT00662311
COMPLETED Phase 2

Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain

NCT00524420
COMPLETED NA

Management of Pain in Persons With Multiple Sclerosis

NCT00621374
COMPLETED NA

Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery

NCT00494832
COMPLETED

Host Response to Urinary Tract Infection in Women

NCT00642070
COMPLETED NA

Ear Drops for Children With Otitis Media

NCT00622518
COMPLETED Phase 2

Perioperative Therapy for Resectable Pancreatic Cancer

NCT00609336
COMPLETED Phase 3

Stimulant Abuser Groups to Engage in 12-Step

NCT00573183
COMPLETED Phase 1

ACY-7 Oral Administration of Acyline

NCT00603187
COMPLETED NA

Early Connections, Early Detection and Intervention in Infants at Risk for Autism

NCT00947700
COMPLETED NA

Computer Assisted Relaxation Learning for Dental Offices

NCT00609648
TERMINATED Phase 4

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716
COMPLETED Phase 1

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

NCT00601718
COMPLETED NA

Reducing Brief Thermal and Electrical Pain (Four Study Days)

NCT00682682
COMPLETED Phase 2

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

NCT00552409
COMPLETED NA

Interpersonal and Social Rhythm Therapy for Adolescents With Bipolar Disorder

NCT00576355
COMPLETED Phase 1

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00602225
COMPLETED Phase 2

Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest

NCT00391469
COMPLETED Phase 4

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT00527618
COMPLETED Phase 2

Exercise After an ICD

NCT00522340
TERMINATED

Hypertonic Modulation of Inflammation Following Injury

NCT00750997
COMPLETED NA

A Practical Model to Transform Childhood Asthma Care - Spirometry Training in the Primary Care Setting

NCT01161433
COMPLETED Phase 2

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00564733
COMPLETED NA

Life Improvement Following Traumatic Brain Injury

NCT00878150
COMPLETED NA

Pain Control After Trauma

NCT00739076
COMPLETED Phase 2

Randomized Clinical Trial of Nasal Turbinate Reduction to Improve Continuous Positive Airway Pressure (CPAP) Outcomes for Sleep Apnea

NCT00503802
COMPLETED Phase 4

Washington State Community Expedited Partner Treatment (EPT) Trial

NCT01665690
COMPLETED Phase 2

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

NCT00519896
COMPLETED NA

Starting Healthy Staying Healthy Pilot Trial

NCT00503074
COMPLETED Phase 4

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

NCT00592384
COMPLETED NA

Virtual Reality Hypnosis for Chronic Pain Reduction

NCT01099657
COMPLETED Phase 2

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT00513695
COMPLETED NA

SPHERE Hypertension Intervention Study

NCT00495833
COMPLETED Phase 1

Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]

NCT00490022
COMPLETED

HSV-2 Shedding Resolution After Acyclovir Treatment

NCT00495573
COMPLETED Phase 1

ACY-6 Oral Administration of Acyline

NCT00471185
COMPLETED NA

Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)

NCT00446394
← Previous Page 18 of 21 Next →

Phase Distribution

PhaseTrial count
Phase 1 127
Phase 2 193
Phase 3 39
Phase 4 65

Therapeutic Areas

Depression 13
Chronic Pain 9
Dementia 8
Multiple Sclerosis 8
Post Traumatic Stress Disorder 7
Stage IV Breast Cancer 6
Pain 6
Anatomic Stage IV Breast Cancer AJCC v8 6
Anatomic Stage III Breast Cancer AJCC v8 6
Spinal Cord Injuries 6

What is open in the University of Washington pipeline

156 recruiting of 1,048 indexed (15% open); 720 completed (69%).

Phase mix: 104 late (III/IV) vs 320 early (I/II) (early-phase heavy).

Top condition: Depression (13 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Washington: open-pipeline peers nationwide

Peers matched on 1,048 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 6%8%10%12%14%16% Total trials Recruiting share University of WashingtonUniversity of Wisconsin, MadisonBristol-Myers SquibbUniversity of FloridaUniversity of North Carolina, Chapel HillDompé Farmaceutici S.p.AVanderbilt-Ingram Cancer CenterArizona State UniversityGeorgetown University
University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,048 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Washington page

1,048 registered trials is a research-attention snapshot, not an endorsement of University of Washington or any single study.

  • 156 of University of Washington's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of Washington studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Washington pipeline card: 1,048 registered trials from official public datasets.Report a data error.